Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis
Open accessThe DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis is a complex autoimmune disease, and several therapies for multiple sclerosis have been developed and widely used. However, existing medications for multiple sclerosis were far from satisfactory due to their failure to suppress relapses and alleviate disease progression. Novel drug targets for multiple sclerosis prevention are still needed. We performed Mendelian randomization to explore potential drug targets for multiple sclerosis using summary statistics from the International Multiple Sclerosis Genetics Consortium (nCase = 47 429, nControl = 68 374) and further replicated in UK Biobank (nCase = 1356, nControl = 395 209) and FinnGen cohorts (nCase = 1326, nControl = 359 815). Genetic instruments for 734 plasma and 154 CSF proteins were obtained from recently published genome-wide association studies. The reverse causality detection using bidirectional Mendelian randomization analysis and Steiger filtering, Bayesian co-localization, and phenotype scanning that searched previously reported genetic variant–trait associations were implemented to consolidate the Mendelian randomization findings further. In addition, the protein–protein interaction network was performed to reveal potential associations among proteins and/or present multiple sclerosis medications. At Bonferroni significance (P < 5.63 × 10−5), Mendelian randomization analysis revealed six protein–multiple sclerosis pairs. In plasma, per standard deviation increase in FCRL3, TYMP and AHSG had a protective effect. Odds ratios for the proteins above were 0.83 (95% CI, 0.79–0.89), 0.59 (95% CI, 0.48–0.71) and 0.88 (95% CI, 0.83–0.94), respectively. In CSF, per 10-fold increase in MMEL1 (OR, 5.03; 95% CI, 3.42–7.41) increased the risk of multiple sclerosis, while SLAMF7 (OR, 0.42; 95% CI, 0.29–0.60) and CD5L (OR, 0.30; 95%CI, 0.18–0.52) decreased the risk. None of the six proteins had reverse causality. Bayesian co-localization suggested that FCRL3 [coloc.abf-posterior probability of hypothesis 4 (PPH4) = 0.889], TYMP (coloc.susie-PPH4 = 0.896), AHSG (coloc.abf-PPH4 = 0.957, coloc.susie-PPH4 = 0.973), MMEL1 (coloc.abf-PPH4 = 0.930) and SLAMF7 (coloc.abf-PPH4 = 0.947) shared the same variant with multiple sclerosis. FCRL3, TYMP and SLAMF7 interacted with target proteins of current multiple sclerosis medications. MMEL1 was replicated in both UK Biobank and FinnGen cohorts. Our integrative analysis suggested that genetically determined levels of circulating FCRL3, TYMP, AHSG, CSF MMEL1 and SLAMF7 had causal effects on multiple sclerosis risk. These findings suggested those five proteins might be promising drug targets for multiple sclerosis and warrant further clinical investigation, especially FCRL3 and SLAMF7.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MR uses genetic variants as instrumental variables, providing robust causal inference and offering insight into the biological pathways driving disease progression [16,17].”
From Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization (2025) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1131 · Cited by 17,749 · cited 1×
“28 In addition, we conducted MR by Wald ratio method and Bayesian co-localization by coloc.abf algorithm with prioritized proteins as both exposure and outcome.”
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728 · cited 7×
“Finally, using the GWAS data from the UK Biobank 13 and FinnGen 14 cohorts and plasma pQTL data from two newly published studies, 15,16 we replicated the analysis as an exter-nal validation to strengthen our conclusion.”
InfluentialDrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404 · cited 1×
“27 We also searched current medications targeting the identified potential causal proteins.”
Mendelian randomization: genetic anchors for causal inference in epidemiological studies
Davey Smith, G., & Hemani, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu328 · Cited by 4,677 · cited 1×
“23 Complete summary statistics for proteins were obtained from three previous studies.”
Giambartolomei, C., Vukcevic, D., Schadt, E. E., Franke, L., Hingorani, A. D., Wallace, C., & Plagnol, V. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004383 · Cited by 4,261 · cited 1×
“…for posterior probability, five proteins identified by MR (FCRL3, TYMP, AHSG, MMEL1 and SLAMF7) were likely to share the same variant of MS. 33 Four of the five identified proteins (FCRL3, TYMP, AHSG and MMEL1) were found to be associated with other traits via phenotype scanning, but none…”
Orienting the causal relationship between imprecisely measured traits using GWAS summary data.
Hemani, G., Tilling, K., & Davey Smith, G. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1007081 · Cited by 2,607 · cited 1×
“We also conducted Steiger filtering to ensure the directionality of the association between proteins and MS. 24 The results were considered statistically significant at P < 0.05.”
InfluentialGenomic atlas of the human plasma proteome
Sun, B. B., Maranville, J. C., Peters, J. E., Stacey, D., Staley, J. R., Blackshaw, J., Burgess, S., Jiang, T., Paige, E., Surendran, P., et al. (2018) · Nature · doi:10.1038/s41586-018-0175-2 · Cited by 2,268 · cited 2×
“12,16,18 The effect was estimated using MR-IVW, MR-Egger, weighted median, simple mode and weighted mode.”
PhenoScanner V2: an expanded tool for searching human genotype–phenotype associations
Kamat, M. A., Blackshaw, J. A., Young, R., Surendran, P., Burgess, S., Danesh, J., Butterworth, A. S., & Staley, J. R. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz469 · Cited by 2,155 · cited 1×
“Phenotype scanning was conducted via both ‘phe-noscanner’ 26 and looking up in the study of Ferkingstad et al .”
Dobson, R., & Giovannoni, G. (2019) · European Journal of Neurology · doi:10.1111/ene.13819 · Cited by 2,148
Guidelines for performing Mendelian randomization investigations
Burgess, S., Davey Smith, G., Davies, N. M., Dudbridge, F., Gill, D., Glymour, M. M., Hartwig, F. P., Holmes, M. V., Minelli, C., Relton, C. L., et al. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15555.1 · Cited by 1,834
Cited by
Åkesson, J., Hojjati, S., Hellberg, S., Raffetseder, J., Khademi, M., Rynkowski, R., Kockum, I. S., Altafini, C., Lubovac-Pilav, Z., Mellergård, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42682-9 · Cited by 116
Does co-localization analysis reinforce the results of Mendelian randomization?
Yin, Q., & Zhu, L. (2023) · Brain · doi:10.1093/brain/awad295 · Cited by 70
Zou, X., Wang, L., Wang, S., Zhang, Y., Ma, J., Chen, L., Li, Y., Yao, T., Zhou, H., Wu, L., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000922 · Cited by 37
“…(such as proteomics) and outcome (IS) in a genetic context and excludes the in fl uence of confounding factors on causality with the aid of multiple sensitivity analyses [9] , and the exclusion of potential confounding factors is one of its advantages over traditional observational studies [10] .”
BackgroundMethodInfluentialProteome-wide mendelian randomization study implicates therapeutic targets in common cancers
Ren, F., Jin, Q., Liu, T., Xuelei, R., & Zhan, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04525-5 · Cited by 40
“…cancer; CCa: colorectal cancer; BLCa: bladder cancer; OCa: ovarian cancer; KCa: kidney cancer; GCa: gastric cancer; cis-pQTL: cis-protein quantitative trait loci; PPH4: posterior probability of hypothesis 4 variation strategy, which utilized genome-wide significant SNPs as genetic instruments [28].”
BackgroundQiu, X., Guo, R., Wang, Y., Zheng, S., Wang, B., & Gong, Y. (2024) · Communications Biology · doi:10.1038/s42003-024-06755-9 · Cited by 24
“…MR (SMR) and two-sample MR (TSMR) enable to estimate pleiotropic or potentially causal associations between genetically determined traits (e.g., gene expression, DNA methylation and protein expression) and complex traits of interest (disease phenotypes as outcomes, e.g., tumors) 16 – 19 .”
Bai, Y., Wang, J., Feng, X., Xie, L., Qin, S., Ma, G., & Zhang, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1419363 · Cited by 23
Yang, L., Ou, Y., Wu, B., Liu, W., Deng, Y., He, X., Chen, Y.-L., Kang, J., Fei, C.-J., Zhu, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49782-0 · Cited by 27
Sun, D., Wang, R., Du, Q., Zhang, Y., Chen, H., Shi, Z., Wang, X., & Zhou, H. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04892-7 · Cited by 19
“Leave-one-out analysis checks whether MR estimates are driven by individual SNPs. Additionally, we employed the Steiger test to mitigate the impact of reverse causation [37, 38].”
MethodTang, C., Chen, P., Xu, L.-L., Lv, J., Shi, S., Zhou, S., Liu, L., & Zhang, H. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000379 · Cited by 20
“11 In 12 – 14 Regarding IgA nephropathy, the exploration of potential key proteins remains limited, which might provide new insights into the biological mechanisms involved.”
Xie, Z.-W., He, Y., Feng, Y., & Wang, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1372221 · Cited by 22
Wang, S., Xi, J., Zhang, M., & Wang, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.139394 · Cited by 21
Lv, X., Liu, W., Zhou, X., Yang, Y., Zhao, W., Meng, L., Mu, F., Zhang, Z., Zhu, S., Zhang, S., et al. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s506221 · Cited by 19
“11 Besides pQTL, regions of methylation and expression of quantitative trait loci (mQTL and eQTL) in the genome often undergo mutations, affecting disease susceptibility.”
Li, X., Lu, Z., Qi, Y., Chen, B., & Li, B. (2023) · Nutrients · doi:10.3390/nu15224787 · Cited by 19
Taylor, H., Lewins, M., Foody, M. G. B., Gray, O. P., Bešević, J., Conroy, M. C., Collins, R., Lacey, B., Allen, N. E., & Burkitt-Gray, L. (2025) · Neurology Genetics · doi:10.1212/nxg.0000000000200226 · Cited by 27
Ni, F.-D., Wang, F., Sun, J., Tu, M., Chen, J., Shen, X., Ye, X., Chen, R., Liu, Y., Sun, X., et al. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2024.10.008 · Cited by 16
“42 To assess the potential of identified proteins as potential therapeutic targets, we also extracted the druggable profile of candidate target proteins from the Drugbank.”
Multiomics integration prioritizes potential drug targets for multiple sclerosis
Jiang, Y., Liu, Q., Stridh, P., Kockum, I. S., Olsson, T. P., Alfredsson, L. S., Díaz-Gallo, L.-M., & Jiang, X. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2425537122 · Cited by 18
“In plasma, a study identified the proteins FCRL3, TYMP, and AHSG as potential drug targets for MS treat-ment ( 14 ).”
Ze-fang, L., Wu, X., Yan, Z., Cui, Y., Liu, Y., Cui, S., Wang, Y., & Liu, T. (2024) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2024.105412 · Cited by 16
Identifying Potential Drug Targets for Keloid: A Mendelian Randomization Study
Wang, Y., Wang, X., Yuan, Z., Liu, F., Luo, X., & Yang, J. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.04.023 · Cited by 15
Sun, D., Wang, R., Du, Q., Chen, H., Shi, Z., Zhang, Y., Zhang, N., Wang, X., & Zhou, H. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.07.135 · Cited by 12
Proteome-wide Mendelian randomization identified potential drug targets for migraine
Xiong, Z., Zhao, L., Mei, Y., Qiu, D., Li, X., Zhang, P., Zhang, M., Cao, J., & Wang, Y. (2024) · The Journal of Headache and Pain · doi:10.1186/s10194-024-01853-9 · Cited by 17
Causal association of sleep traits with the risk of thyroid cancer: A mendelian randomization study
Zong, L., Liu, G., He, H., & Huang, D. (2024) · BMC Cancer · doi:10.1186/s12885-024-12376-6 · Cited by 14
“As the genetic code cannot be influenced by environmental factors or preclinical diseases, it is also less susceptible to bias caused by reverse causation [11].”
BackgroundYi, G., Li, Z., Sun, Y., Ma, X., Wang, Z., Chen, J., Cai, D., Zhang, Z., Chen, Z., Wu, F., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05856-7 · Cited by 15
Identifying novel potential drug targets for endometriosis via plasma proteome screening
Tao, T., Mo, X., & Zhao, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1416978 · Cited by 12
Causal factors for osteoarthritis risk revealed by mendelian randomization analysis
Luo, Q., Zhang, S., Yang, Q., Deng, Y., Yi, H., & Li, X. (2024) · Aging Clinical and Experimental Research · doi:10.1007/s40520-024-02812-9 · Cited by 12
Identification of Potential Biomarkers and Therapeutic Targets for Periodontitis
Huoshen, W., Zhu, H., Xiong, J., Chen, X., Mou, Y., Hou, S., Yang, B. T., Yi, S., He, Y., Huang, H., et al. (2024) · International Dental Journal · doi:10.1016/j.identj.2024.10.006 · Cited by 12
Wang, J., Hu, J., Qin, D., Han, D., & Hu, J. (2024) · World Allergy Organization Journal · doi:10.1016/j.waojou.2024.101008 · Cited by 12
“This choice was made based on current research suggesting that utilizing cis -acting data might be preferable, as opposed to using a larger number of SNPs. 14 Therefore, to enhance the reliability of our results, we opted to select only robust instrumental variables with an F-value greater than 10 as described before.”
InfluentialFan, H., Li, J., Dou, Y., Yan, Y., Wang, M., Yang, X. Q., & Ma, X. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03196-0 · Cited by 14
Khan, Z., Mehan, S., Maurya, P. K., Kumar, A., Gupta, G. D., Narula, A. S., & Kalfin, R. E. (2025) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303325979241206115417 · Cited by 15
Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization
Xu, D., Lu, J., Yang, Y., Hu, W., Chen, J., Xue, J., Yang, S., Cao, N., Hu, H., Qian, N., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119110 · Cited by 10
Genetic associations in ankylosing spondylitis: circulating proteins as drug targets and biomarkers
Zhang, Y., Liu, W., Lai, J., & Zeng, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1394438 · Cited by 15
“These analyses were performed using Metascape (http://metascape.org) and the Oebiotech platform (https://cloud.oebiotech.cn/, last accessed on 12 January 2024) (27).”
MethodYu, K., Jiang, R., Li, Z., Ren, X., Jiang, H., & Zhao, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1428962 · Cited by 11
Lin, Y., Zhang, Y., Wang, S., Cao, L. S., Zhao, R., Ma, X., Yang, Q., Zhang, L.-Y., & Yang, Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1443045 · Cited by 11
Gao, J., Yuan, L., Jiang, H., Li, G., Zhang, Y., Zhou, R., Xian, W., Zou, Y., Du, Q., & Zhou, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1448308 · Cited by 13
“This method was used to assess the posteriori probabilities for fi ve hypotheses, as previously mentioned (Lin et al., 2023), regarding whether a single variant was shared between the two features.”
BackgroundMethodInfluentialDong, Q., Wu, J., Zhang, H., Luo, L., & Wu, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1412298 · Cited by 11
“If the posterior probability of hypothesis 4 (PPH4) exceeded 80%, it was considered signi fi cant evidence supporting the colocalization of genes (23).”
BackgroundLi, C., Zhang, K., & Zhao, J. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.01.140 · Cited by 9
Identification of potential drug targets for varicose veins: a Mendelian randomization analysis
Lin, J., Zhou, J., Liu, Z., Zeng, R., Wang, L., Li, F., Cui, L., & Zheng, Y. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1126208 · Cited by 9
“MR has been used successfully in previous studies to identify biomarkers and therapeutic targets in a wide range of diseases, including stroke (13), multiple sclerosis (14), and type 1 diabetes (15).”
MethodSelf-citationJin, Q., Ren, F., & Song, P. (2024) · Autoimmunity · doi:10.1080/08916934.2024.2330392 · Cited by 9
“…(i) the pQTLs were cis -acting pQTLs and were not located within the major histocompatibility complex region (chr6, 26–34Mb); (ii) the pQTLs exhibited significant associations with the respective protein expression levels ( p < 5E − 08); (iii) the pQTLs were not interfered by LD (r 2 <0.001) [17].”
InfluentialXue, H., Chen, J., & Fan, W. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.04.006 · Cited by 10
Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis
Ouyang, Y., Chen, Y., Chen, K., Tang, Z., Shi, G., Qu, C., Zhang, K.-Y., & Yang, H. (2024) · Human Genomics · doi:10.1186/s40246-024-00607-7 · Cited by 9
“MR analyses also pro-pose potential therapeutic targets for multiple sclerosis (MS) and numerous neurodegenerative diseases [10, 11].”
BackgroundStructural variants in linkage disequilibrium with GWAS-significant SNPs
Liang, H., Sedillo, J. C., Schrodi, S. J., & Ikeda, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32053 · Cited by 11
“In a large proteome study utilizing Mendelian randomization which included cerebral spinal fluid samples, increased levels of MMEL1 protein was found to have significant effects on inflating multiple sclerosis risk, suggesting a causal role of MMEL1 in multiple sclerosis pathogenesis [63].”
BackgroundXie, J., Ma, R., Xu, X. P., Yang, M., Yu, H., Wan, X., Xu, K., Guo, J., & Xu, P. (2024) · Clinical Rheumatology · doi:10.1007/s10067-024-07136-7 · Cited by 9
WNT inhibitor SP5-mediated SERPING1 suppresses lung adenocarcinoma progression via TSC2/mTOR pathway
Shen, Y., Dong, X., Li, X., Shi, Z., Shao, T., Jiang, J., & Song, J. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07440-3 · Cited by 8
Li, M., Shi, P., Yang, H., Tong, S., Qiu, N., Yao, F., Du, Y., Xi, S., & Wang, F. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.115896 · Cited by 8
Jiang, R., Huang, W., Qiu, X., Chen, J., Luo, R., Zeng, R., Tong, S., Lyu, Y., Sun, P., Lian, Q., et al. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae353 · Cited by 10
Wang, H., Pang, J., Zhou, Y., Qi, Q., Tang, Y., Gul, S., Sheng, M., Dan, J., & Tang, W. (2024) · Clinical and Translational Allergy · doi:10.1002/clt2.12350 · Cited by 8
“15,68,69 When we have more GWAS data on allergic diseases from additional ancestral backgrounds, we plan to conduct supplementary studies.”
Zhang, C., Jian, L., Li, X., Guo, W., Deng, W., Hu, X., & Li, T. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105197 · Cited by 9
Zhang, K., Shi, P., Li, A., Zhou, J., & Chen, M. (2024) · Respiratory Research · doi:10.1186/s12931-024-03008-5 · Cited by 7
“Recently, Mendelian randomization (MR) analysis has been widely used to study causal associations and identify potential drug targets [14].”
BackgroundSelf-citationC-reactive protein and cognitive impairment: A bidirectional Mendelian randomization study
Xie, W., Kong, C., Luo, W., Zheng, J., & Zhou, Y. (2024) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2024.105359 · Cited by 10
Li, D., Zhang, Z., Zhang, C. L., Guo, Q., Chen, C., & Peng, X. (2024) · Endocrine · doi:10.1007/s12020-024-03745-z · Cited by 8
Yao, T., Lin, Y.-L., Wu, Y., Qian, X.-G., Wang, Z.-N., Qian, S., Jiang, T., Liu, J., Fang, L.-X., Zhen, C., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1407795 · Cited by 7
“The ef fi cacious application of drug-targeted MR analyses has extended to various disorders, such as multiple sclerosis (9), type 1 diabetes (10), and COVID-19 (11).”
Dong, B., Wang, M., Li, K., Li, Z., Liu, L., & Shen, S. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae110 · Cited by 9
Perturbation response scanning of drug-target networks: Drug repurposing for multiple sclerosis
Lu, Y., Zhou, Z., Li, Q., Yang, B., Xu, X. Y., Zhu, Y., Xie, M., Qi, Y., Xiao, F., Yan, W., et al. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101295 · Cited by 7
Jin, Q., Ren, F., & Song, P. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2292605 · Cited by 7
“Consistent with previous studies, we used two approaches to screen for genetic proxies for ACEIs: (i) protein Quantitative Trait Loci (pQTL) significantly correlated with the expression of circulating ACE in plasma; and (ii) SNPs targeting ACE to reduce DBP or SBP [25,26].”
BackgroundMethodInfluentialLin, Y.-L., Yao, T., Wang, Y., Zhou, Z., Hong, Z., Shen, Y., Yan, Y., Li, Y., & Lin, J. (2024) · Journal of Human Genetics · doi:10.1038/s10038-024-01234-9 · Cited by 8
“ERBB3, ANTR2, and DUSP13 exhibited signi fi cant correlations with body composition traits, such as whole-body fat mass and body fat percentage, which are closely linked to GERD incidence.”
Self-citationSystematic Analysis of the Relationship Between Elevated Zinc and Epilepsy
Luo, D., Liu, Y., Li, J., Liu, X., Zhang, R., Liu, X., Zhang, N., Zhang, W., Liu, J., Zhang, L., et al. (2024) · Journal of Molecular Neuroscience · doi:10.1007/s12031-024-02213-7 · Cited by 7
“…there are certain genes that can significantly affect two traits at the same time, based on a portion of the genetic data that is common to the two traits, using univariate sum-mary statistics to test whether there are two independently related genetic traits at the same locus (Lin et al. 2023).”
Genetic variation reveals the therapeutic potential of BRSK2 in idiopathic pulmonary fibrosis
Chen, Z., Tang, M., Wang, N., Liu, J., Tan, X., Ma, H., Luo, J., & Xie, K. (2025) · BMC Medicine · doi:10.1186/s12916-025-03848-y · Cited by 8
Mendelian randomization analysis to identify potential drug targets for osteoarthritis
Lu, C., Xu, Y., Chen, S., Guo, L., Li, P., Wei, X., & Rong, X. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316824 · Cited by 8
Self-citationXu, Y., Zhang, X., Zhang, Y., Ma, H., Zhou, Z., Qin, H., Liu, H., & Han, X. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106929 · Cited by 7
Self-citationWang, Y., Chen, G., & Deng, L. (2024) · Biology Direct · doi:10.1186/s13062-024-00587-7 · Cited by 6
“For the causal effects of Zheng Plasma Protein cis-pQTLs on ED, IVs were provided in the article of Zheng et al. [3]; two-sample MR analysis was conducted, and the inverse variance weighting (IVW) or the weighted median P-values below 0.05 were regarded as statistically significant [7].”
Influentialc-JUN interacts with HDAC1 as a potential combinatorial therapeutic target in acute myeloid leukemia
Wu, K., Xu, X., Wei, W., Wen, J., & Hu, H. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113927 · Cited by 6
Zhang, X., Peng, N., Zhang, X., Zhu, Z., Yan, M., Wu, Y., Ling, J., Li, C., Gu, W., Zhang, J., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01712-w · Cited by 9
“…associations: H0) neither trait is associated with the locus; H1) only trait 1 is associated with the locus; H2) only trait 2 is associated with the locus; H3) both traits are associated, but with different causal variants; and H4) both traits are associated and share the same causal variant [25].”
Li, X., Yan, Z., Hongrong, L., Wu, Y., Chen, S., Qiu, G., & Wu, Y. (2025) · Experimental Dermatology · doi:10.1111/exd.70158 · Cited by 7
“SNPs enriched in vascular tissues may promote NF-κB activation, up-regulating VCAM-1 and ICAM-1 and accelerating monocyte infiltration and atherosclerosis [44, 45].”
Su, Z., & Wan, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1342912 · Cited by 8
Exploration of potential novel drug targets for diabetic retinopathy by plasma proteome screening
Yuan, W., Xu, W., Xu, X., Qu, B., & Zhao, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-62069-0 · Cited by 6
“At present, this MR method has been widely recognized and has been used to identify therapeutic targets for multiple sclerosis, asthma, small cell lung cancer and other diseases 12 .”
MethodOu, H., Huang, H., Xu, Y., Lin, H., & Wang, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107662 · Cited by 9
Self-citationDing, S., Zhang, Y., Tang, Y., Zhang, Y., & Liu, M. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1437778 · Cited by 8
Uncovering drug targets for cluster headache through proteome-wide Mendelian randomization analysis
Xiong, Z., Guo, Z. K., Zhao, L., Qiu, D., Mei, Y., Li, X., Zhang, P., Zhang, M., Liu, G., Gao, T., et al. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-01999-0 · Cited by 5
Jia, T., Liu, T., Hu, S., Li, Y., Chen, P., Qin, F., He, Y., Han, F., & Zhang, C. (2024) · Psychological Medicine · doi:10.1017/s0033291724001077 · Cited by 6
“Recent advances have been made in identifying new drug targets for multiple diseases, including multiple sclerosis (Lin, Zhou, & Xu, 2023), ischemic stroke (Chong et al., 2019), and Alzheimer ’ s disease (Wingo et al., 2021), by combining GWAS and pQTL data.”
Cui, Y., Hu, M., Zhou, H., Guo, J., Wang, Q., Xu, Z., Chen, L., Zhang, W., & Tang, S. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1385293 · Cited by 5
“MR has been successfully used in previous studies to identify biomarkers and treatment targets for various diseases, including aortic aneurysms (Chen et al., 2022), multiple sclerosis (Lin et al., 2023b), and breast cancer (Wang et al., 2023).”
BackgroundMethodGao, Y., Zhou, Y., Lin, Z., Chen, F., Wu, H., Peng, C., & Xie, Y. (2024) · Clinical Rheumatology · doi:10.1007/s10067-024-07059-3 · Cited by 5
Proteomic Mendelian randomization to identify protein biomarkers of telomere length
Zhao, J., Yang, K., Lu, Y., Zhou, L., Fu, H., Feng, J., & Wu, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-72281-7 · Cited by 8
“We considered that PPH4 (posterior probability that protein and TL shared the same causal variant) greater than 80% constitutes robust evidence in favor of colocalization 29,30 .”
BackgroundWu, Q. Y., Geng, Z., Lu, J., Wang, S., Yu, Z., Wang, S., Ren, X., Guan, S., Liu, T., & Chen, Z. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1467562 · Cited by 8
Yoshikawa, M., Nakayama, T., & Asaba, K. (2024) · Communications Biology · doi:10.1038/s42003-024-07403-y · Cited by 5
“The estimated causal effect was equivalent to the log e OR of each skin cancer per standard deviation increase in plasma protein levels 10,58 .”
Liu, S., Li, L., Liang, Y., Tan, Y., Wang, X., Feng, Y., Chen, N., & Xia, L. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf032 · Cited by 7
Guo, C., Li, J., Yang, X., Xie, W., Zeng, F., Chen, K., Mi, W., Tang, C. C., & Wang, H. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156339 · Cited by 4
Yuan, Y., Liang, X., Kang, S., & Liu, Y. (2025) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-025-06374-y · Cited by 4
“The advantage of MR analysis is that it utilizes genotypes determined at the time of fertilization, minimizing bias due to confounding factors and reverse causality [14].”
Xing, X., Xu, S., Wang, Y., Shen, Z., Wen, S., Zhang, Y., Ruan, G., & Cai, G. (2024) · Diabetes · doi:10.2337/db24-0262 · Cited by 5
Chen, P., Wei, X. C., Li, X., Zhou, Y., Liu, Q., & Ouyang, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1371498 · Cited by 5
Identification and catalog of viral transcriptional regulators in human diseases
Citu, C., Chang, L., Manuel, A. M., Enduru, N., & Zhao, Z. (2025) · iScience · doi:10.1016/j.isci.2025.112081 · Cited by 4
Liu, Y., Li, C., Yao, L., Tian, M., Tan, Y., Shi, L., & Chen, P. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01607-4 · Cited by 5
“Advances in high-throughput genomics and proteomics have facilitated the identification of potential therapeutic targets for neurological disorders such as multiple sclerosis and ischemic stroke (Lin et al. 2023; Chong et al. 2019).”
Insight into telomere regulation: road to discovery and intervention in plasma drug-protein targets
Ding, K., Zhangwang, J., Lei, M., & Xiong, C. (2024) · BMC Genomics · doi:10.1186/s12864-024-10116-5 · Cited by 4
“…the use of genetic variants associated with protein expression regulatory loci (pQTL) as exposure variables for MR, has been applied to the identification of potential drug targets for various diseases, such as multiple sclerosis, inflammatory bowel disease, and Parkinson’s disease [17–19].”
InfluentialIdentification of potential biomarkers for neuromyelitis optica by quantitative proteomics
Ding, Y., Chen, Y., Sun, J., Shi, Y., Li, G., Luan, X., Wang, S., Li, X., Jiang, W., Wang, L., et al. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52033 · Cited by 4
Xu, D., Yang, X., Wu, W., & Yang, J. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s463450 · Cited by 5
“13 Second, we corroborated the initial findings through various methods including Bayesian co-localization analysis, reverse MR, and phenotype scanning.”
BackgroundMethodWang, S.-K., Wang, Q., Zhao, X., Wang, P., Li, X., Wang, W., & Lu, S. (2024) · The journal of nutrition health & aging · doi:10.1016/j.jnha.2024.100325 · Cited by 5
“In the primary MR, we used the plasma proteins as the exposure and low HGS as the outcome to perform a two-sample MR referring to the study by Lin et al. [7].”
InfluentialLiu, S., Zhou, X., Zhang, L., & Luo, W. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37584 · Cited by 4
“Mendelian randomization (MR) is a powerful statistical method for exploring causal relationships between targets and diseases [16], and has played a key role in drug target research in recent years [17].”
BackgroundWang, T., Ma, P., Wang, X., & Xia, Y. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04209-y · Cited by 4
“…the core assumption of MR analysis) pQTL/eQTL data and GWAS phenotype data combined with sensitivity analysis including bidirectional Mendelian randomization analysis and Steiger filtering was used to identify potential causal plasma proteins for diseases to find new therapeutic targets [14–16].”
MethodChen, M., Xu, X., Wang, F., & Xu, X. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1466799 · Cited by 5
Lin, Q., Li, J., Sun, Y., Abudousalamu, Z., Xue, M., Yao, L., & Chen, M. (2024) · International Journal of Women s Health · doi:10.2147/ijwh.s491414 · Cited by 3
Fang, C., Liu, X., Yu, C., Li, S., Liu, X., Qiu, S., Liang, H., Ou, C., & Xiu, J. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-06027-4 · Cited by 6
Potential drug targets for asthma identified through mendelian randomization analysis
Chen, X., Shang, Y., Shen, D., Shi, S., Wen, Z., Li, L., & Chen, H. (2025) · Respiratory Research · doi:10.1186/s12931-024-03086-5 · Cited by 6
“Mendelian randomization (MR) is a statistical analysis in genetics that can predict the efficacy of drugs by mimicking randomised controlled trials, and has been widely used in drug target development and drug repurposing [12–14].”
Altalbawy, F. M. A., Bakhtiyarovna, B. Z., Baldaniya, L., Singh, A., Singh, K. U., Ballal, S., Sabarivani, A., Sead, F. F., Alam, R., & Alshahrani, M. Y. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114516 · Cited by 5
Association of gut microbiota with cerebral cortical thickness: A Mendelian randomization study
Shi, L., Liu, X., Zhang, S., & Zhou, A. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.02.063 · Cited by 4
Utilizing systematic Mendelian randomization to identify potential therapeutic targets for mania
Xu, F.-B., Hu, S., Wang, J., & Wang, X. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1375209 · Cited by 4
“…selected genome-wide signi fi cant single nucleotide polymorphisms ( p 5e-06) and tested linkage disequilibrium (r 2 = 0.001, kb=10000) as instrumental variables, eliminating the single nucleotide polymorphisms in linkage disequilibrium to ensure the independence of the instrumental variables (13).”
MethodInfluentialWang, Q., Chen, S., Wang, G., Zhang, T., & Gao, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-12513-1 · Cited by 4
“Additionally, phenotype scanning (http://www.phenoscanner.medschl.cam.ac.uk/) was used to lessen the impact of confounding variables and ensure the MR independence assumption [22].”
MethodZhu, X., Qiu, Z., Yang, M., Yang, J., Kong, L., Li, L., Huang, Y., & Xie, L. (2024) · Journal of Cancer · doi:10.7150/jca.96059 · Cited by 4
“Furthermore, considering ethical concerns, it is not feasible to measure causal relationships in experimental settings.”
BackgroundLei, J., He, W., Liu, Y., Zhang, Q., Liu, Y., Ou, Q., Wu, X., Li, F., Liao, J., & Xiao, Y. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1377719 · Cited by 3
Causality between diabetes and membranous nephropathy: Mendelian randomization
Su, Z., Luo, Z., Wu, D., Liu, W., Li, W., Yin, Z., Xue, R., Wu, L., Cheng, Y. Z., & Wan, Q. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02566-8 · Cited by 4
“MR is an analytical method to infer causal relationships between exposures and outcomes [14].”
Genetic insights into drug targets for alzheimer’s disease: integrative multi-omics analysis
Liu, X., Chen, J., Zhou, S., & Lin, J. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01901-9 · Cited by 4
Self-citationVitamin D deficiency and multiple sclerosis relapse: a meta-analysis
Zhang, Y., Yu, S., Zu, Y., Lv, J., Chen, J., & Feng, X. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2025.1727615 · Cited by 3
“The high-dose group included 2 studies, with a MD of 43.99 (95%CI [10.61, 77.37]), Z = 2.58, p = 0.01, suggesting that high-dose vitamin D intervention could significantly increase serum 25(OH)D levels, while there was high heterogeneity within the subgroup ( I 2 = 96.69%, p = 0.00).”
InfluentialChen, L., Zuo, Y., He, M., Duo, L., & Tang, W. (2024) · Journal of International Medical Research · doi:10.1177/03000605241272639 · Cited by 3
“20,21 22–25 To address inconsistencies in clinical observations and the lack of in-depth research on SGLT2i and common cardiac diseases, genome-wide association study (GWAS) data were used in two-sample drug-target MR analysis.”
Metadata
- Authors
- Lin, J., Zhou, J., & Xu, Y.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Xu, Yan
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-03-02
- Volume
- 146
- Issue
- 8
- Pages
- 3364-3372
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC10393411
- OpenAlex
- W4323035146
- Cited by
- 271
- References
- 56
- Citations by year
- 2026: 43 · 2025: 87 · 2024: 120 · 2023: 21
- FWCI
- 55.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Peking Union Medical College Deposition Research Fund (ZC201904188)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Mapping and Diversity in Plants and Animals
- Keywords
- multiple sclerosis, therapeutic target, plasma proteins, cerebrospinal fluid protein, FCRL3, SLAMF7, CD5L, fetuin-A, thymidine phosphorylase, reverse causality, protein-protein interaction network, autoimmune disease, genetic risk factors, disease progression, relapse prevention, neuroinflammation, neurodegeneration
- MeSH terms
- Bayes Theorem, Humans, Multiple Sclerosis, Phenotype, Polymorphism, Single Nucleotide, Genome-Wide Association Study, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.